New drug against macular degeneration wins federal approval

Lucentis, made by the South San Francisco, Calif., biotechnology company Genentech Inc., inhibits the growth of blood vessels when injected into the eye. Other Food and Drug Administration-approved treatments can arrest progression of the disease, which can lead to blindness in just weeks or months, but none has been shown to significantly reverse deteriorating vision.

Photo: New drug against macular degeneration wins federal approval

Genentech may find Lucentis competing against another of its drugs, the cancer treatment Avastin. Avastin is increasingly used to treat macular degeneration for as little as $17 a dose. Lucentis is likely to cost upward of $2,000 a dose.

Lucentis and Avastin both block the same protein believed responsible for the blood vessel growth. Early results from Lucentis trials led doctors more than two years ago to begin experimenting with Avastin to treat age-related macular degeneration, commonly called AMD.

Since then, at least 10,000 macular degeneration patients have received Avastin injections, a so-called "off-label" use of the drug.

"It's become a worldwide phenomenon," said Dr. Philip Rosenfeld, a professor of ophthalmology at the Bascom Palmer Eye Institute in Miami who pioneered its use for AMD, the AP reports.

The Food and Drug Administration does not sanction using Avastin to treat macular degeneration. Genentech stresses that it has not studied the safety or effectiveness of Avastin in treating the disease, nor does it plan to do so.